Enteral Lipid Supplementation and Bronchoplumonary Dysplasia of Premature Infants

Recruiting now · Phase 4

Conditions studied: Bronchopulmonary Dysplasia (BPD)

In brief

The Impact of Omega-3 (DHA - Docosahexaenoic Acid) and Omega-6 (ARA - Arachidonic Acid) Supplementation on the Development of Bronchopulmonary Dysplasia in Extremely and Very Preterm Infants (24-29 weeks of gestational age).

Key facts

Study ID

NCT07652684

Run by

Aristotle University Of Thessaloniki

People needed

74

Starts

2025-03-04

Expected to finish

2027-03-01

Last updated by the study team

2026-06-17

Who can join

Age: 0 and older, up to 1. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Infants born at Papageorgiou Hospital in Neonatology Department and NICU of Aristotle University of Thessaloniki with GA equal to or less than 29 weeks are eligible to participate in the study.

You may not qualify if…

• Congenital malformations, chromosomal abnormalities or critical illness with short life expectancy.
• Study participation requires written informed parental consent within 48h after birth.

Where it is running

• Papageorgiou General Hospital — Thessaloniki, Greece (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.